Poly(ADP-ribose) polymerase (PARP) Research Products

Overview:  This PARP Research Products market report explores are a superfamily of 18 proteins, of which PARP-1 is the best characterized. They are enzymes that are activated by DNA breaks to facilitate DNA repair.

Currently, there is a great deal of research being done on this family of polymerases, because its activity is linked to serious disease conditions, including cancer, ischemia, diabetes, arthritis, inflammatory bowel disease, and septic shock. Of greatest therapeutical interest are PARP-1 inhibitors, as they exert a duel effect of inhibiting cell death and reducing inflammation. Indeed, these inhibitors have been shown to be effective as radiation-sensitizing agents and appear promising in the treatment of conditions involving oxidative stress. Additionally, quantification of poly(ADP-ribose) polymerase activity and identification of abnormal patterns of its degradation by proteases might have utility in the diagnosis various conditions.

At this time, there are a limited number of research products available to this research community. Commercially available research tools include enzymes, antibodies, inhibitors, and assay kits designed for the measurement of poly(ADP-ribose) polymerase activity. Because of the size and growth potential of this research products market, providing products to this market niche represents a significant financial opportunity. This report is an in-depth exploration of this research products market, including market conditions, dominant competitors, clinical applications, and product opportunities available to companies interested in this lucrative, early-stage market.

http://www.aarkstore.com/reports/Poly-ADP-ribose-polymerase-PARP-Research-Products-32482.html

Opportunities in Human Embryonic Stem Cell (hESC) Products

Overview:  Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. hESCs are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

hESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.
Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.

This market report recognizes that a wide range of products and services are needed to support this active and well-funded research community. Thus, this report provides:
Discussion of key advances in hESC research

A breakdown of hESC research applications, including shared priorities and priorities by segment

hESC patent analysis

Historical and future growth projections for the hESC market

Competitive analysis of providers of hESC research tools

Overview of specialty pharma companies developing hESC therapies

Overview of toxicology testing legislation impacting use of hESC in toxicology applications

A breakdown of hESC research product categories

Suggestions for novel NSC research products, including cells, kits, assays, media and reagents

Guidance for companies that wish to offer hESCs products

http://www.aarkstore.com/reports/Opportunities-in-Human-Embryonic-Stem-Cell-hESC-Products-32477.html

Strategic Development of Neuronal Stem & Progenitor Cell Products

Overview:  Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo.
 

The terms neuronal and neural also need to be defined. Technically speaking, “neuronal” means “pertaining to neurons”, and “neural” means “pertaining to nerves, which are the cordlike bundles of fibers made up of neurons.” Since both terms ultimately are descriptive of neurons, the scientific community uses the terms “neuronal” and “neural” interchangeably. The complexity of this issue is explored from a marketing perspective within this report.
 

In 1992, Reynolds and Weiss were the first to isolate neural stem cells from the striatal tissue of adult mice brain tissue, including the subventricular zone, which is a neurogenic area. Since then, neural progenitor and stem cells have been isolated from various areas of the adult brain, including non-neurogenic areas like the spinal cord, and from other species, including humans. During the development of the nervous system, neural progenitor cells can either stay in the pool of proliferating undifferentiated cells or exit the cell cycle and differentiate.
 

Over the past few years, neuronal stem and progenitor cells have become of profound interest to the research community due to their potential to be used in drug discovery and delivery applications, as well as for tools of neural toxicology assessment. NSC transplantation also represents a ground-breaking approach for treating a range of chronic neurological diseases and acute CNS injuries, including Parkinson’s, Alzheimer’s and spinal cord injury, among other conditions.
 

This market report focuses on recent advances in NSC research applications, explores research priorities by market segment, highlights individual labs and end-users of neuronal stem cell research products, explores the competitive environment for NSC research products, and provides 5-year growth and trend analysis. It provides detailed guidance for companies that wish to offer strategically positioned NSC research products, including cells, kits, assays, and related media and reagents.

http://www.aarkstore.com/reports/Strategic-Development-of-Neuronal-Stem-Progenitor-Cell-Products-32473.html

Mesenchymal Stem Cells, Advances & Applications – Aarkstore Enterprise

Overview:  Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells.
 

MSCs are of intense therapeutic interest because they represent a population of cells with the potential treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and bone fractures.
 

This market research report focuses on recent advances in MSC research applications, explores research priorities by market segment, highlights individual labs and end-users of MSC research products, explores the competitive environment for MSC research products, and provides 5-year growth and trend analysis. Additionally, this report provides guidance for companies that offer or wish to offer competitive stem cells products to this rapidly growing, well-funded research community.

http://www.aarkstore.com/reports/Mesenchymal-Stem-Cells-Advances-Applications-32470.html

Stem Cell Research Products: Opportunities, Tools & Technologies

Overview:  Since 2001, funding for research on embryonic stem cells has been extremely limited. However, on March 9, 2009, President Obama overturned the order signed by President Bush in 2001 that barred the NIH from funding research on embryonic stem cells beyond using 60 cell lines that existed at that time. This dramatic policy change represents a major opportunity for life science suppliers.
 

The market report, “Stem Cell Research Products: Opportunities, Tools & Technologies” was produced using a detailed end-user survey of research scientists, in which over 400 stem cell researchers from the U.S., Canada, Europe, Asia, Australia and other international regions participated. The findings represent perspectives across a global audience of researchers.
 

As a technology company, BioInformant also used proprietary data-derivation techniques to quantify and assess critical trends in the stem cells marketplace. The result is a high value, full-content report designed to inform the decision-making of research supply companies.
 

Featured elements of this report include:
 

• What are novel stem cells research products that can be developed?
• What stem cells types are most frequently used by research scientists?
• Which species of stem cells do scientists prefer and what are the factors driving this preference (access, pricing, funding, handling advantages)?
• What are the most frequently used stem cell markers?
• What are the most common research applications, and how do they differ by segment (academic, industrial, and government)?
• Who are the leading suppliers of stem cell products?
• What stem cell product categories are already available in the marketplace?
• What are current grant, patent, and scientific publication rate trends?
• What are the major funding sources, trends, and dollar values, for domestic and international researchers?
• What is the size of the stem cell research products marketplace and how fast is it growing?
• What are communication strategies for accessing the marketplace?

  http://www.aarkstore.com/reports/Stem-Cell-Research-Products-Opportunities-Tools-Technologies-32459.html

Capitalizing on Opportunities in Cord Blood Industry Growth –

Overview: Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations. Deeper analysis reveals that of existing cord blood banks, most fall into one of two “camps,” either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (17% or more per annum).

This finding begs the questions:

•What factors are causing a substantial number of new cord blood banks to open up business? Is it the result of a profit opportunity, an effect of advances in therapeutic applications, a social response to more parents being aware of the opportunity to store cord stem cells at birth, or are other factors driving the activity?

•What will be the effect of these new entrants to the cord blood banking industry for existing competitors?

•Perhaps most critically, what are the differences among the cord blood banks that are experiencing flat-line growth, versus those that have substantively built revenue over the past 12 months?
In BioInformant’s initial version of this report, “Choices in Cord Blood Banking – Factors Influencing Parental Decision-Making,” launched April 2009, an survey of 1,200 expectant parents was used to provide a roadmap for how cord blood banks can best communicate and market their services to potential clients. The top-selling report explored the specific reasons that parents elect to store cord blood and what factors influence their decision-making in choosing a specific bank. (Click here to read the Executive Summary for the original version of the report.)

This expanded and updated version includes from the original report, as well as supplemental analysis of factors that have produced double-digit industry growth over the past year. It provides guidance on how to break through flat-line growth to become a fast-growing competitor within the cord blood industry.

Executive Summary

Overview: Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.”
Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the Cord Blood Banking Industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents answered the detailed survey. The survey initially focused on U.S. respondents, but due to international interest was expanded to include respondents from Canada, Mexico, South America, Europe, Asia, Australia, and other regions as well.

Key findings of the report includes:

•Rates of awareness by gender, income, geographic location, and education
•Sources through which expectant parents learn of cord blood preservation
•Factors influencing private vs. public storage of cord blood
•Price sensitivity and quality expectations
•Approaches for communicating with expectant parents
•Key factors influencing the decision to store cord blood
•Parental responsiveness to health statistics
•Trends in cord blood banking
•Competitive analysis of the cord blood banking industry

http://www.aarkstore.com/reports/Capitalizing-on-Opportunities-in-Cord-Blood-Industry-Growth-32359.html

e-Retail: Multichannel retail integration – Aarkstore Enterprise

An increasingly empowered consumer is now internet shopping savvy and has come to expect a consistent experience with whichever channel they choose to shop. With consumers’ expectations and competitive pressures increasing, it is imperative that retailers develop long term multichannel strategies, investing in new technology and incorporating new services in their propositions.

Scope

*Analysis of how the development of multichannel operations has impacted the way in which consumers shop.

*Overview of what the modern consumer has come to expect from their shopping experience.

*The difficulties that have arisen through the creation of multichannel retail operations.

*How retailers can respond to these difficulties and help foster the closer integration and experience consistency between channels.

Highlights

A more empowered and demanding consumer expects a high level of shopping experience regardless of which channel is utilised. It is thus essential that retailers link channels as much as possible, creating a consistent cross-channel experience.

To attain a heightened level of integration across all channels it is essential to invest in unifying both front of house and backoffice operations. In turn this will allow easier and more effective fulfilment strategies and multichannel management of customer data.

New technology such as instore kiosks and more advanced visual imagery online will facilitate the integration of different channels. It is also important for retailers to implement multichannel services such and click & collect, not only to strengthen integration but to enhance convenience credentials.

Reasons to Purchase

*Understand the impact that changing consumer habits have had on their demands and expectations.

*Identify the issues that retailers face when developing multichannel operations and the strategies that they can employ to overcome them.

*Understand what role new instore and online technology can have in achieving closer integration and consistency of experience.

http://www.aarkstore.com/reports/e-Retail-Multichannel-retail-integration-31031.html

UK Neighbourhood Retailing 2008 – Aarkstore Enterprise

Neighbourhood retailing is outperforming all other locations. The location offers substantial opportunities, but the dynamics of the market are changing. As the market consolidates, growth is becoming more elusive and while substantial opportunities remain, trading conditions are more challenging and the strategies for success very different.
 
 Scope
 
 *Key metrics of neighbourhood retail: sales growth, space, store numbers, store sizes and sales densities.
 
 *Detailed market analysis (convenience, off-licences, CTNs, food specialists, pharmacies) and profiles of all the leading neighbourhood retailers
 
 *Focus on composition of convenience market (The Co-operatives, Multiples, Symbol Groups, Independents, forecourt retailing)
 
 *Market shares for leading players 2003-2008
 
 Highlights
 
 Neighbourhood retailing is benefitting from a shift in shopping habits, an increased demand for convenience, improved standards and the arrival of the grocers. The expansion of the grocers has enticed people to shop locally and the symbol groups to enhance their propositions, encouraging independents to join and consumers to shop with them.
 
 Competition is intensifying and pressures on food specialists, independents, off-licences and CTNs mounting. With the market consolidating, the easy wins of the past are harder to come by, while the boost received from the arrival of the grocers can not be repeated. Growth is set to become more elusive and the strategies for success different.
 
 With propositions becoming more comprehensive, the need for CTNs, off-licenses and undifferentiated specialists is diminishing. As the market consolidates, store environments, fresh food and food-to-go will be key battlegrounds and the multiples, with the expertise and investment available to them, are well placed be the big winners.
 
 Reasons to Purchase
 
 *Benchmark retailer performance against the market. Understand the dynamics of the location, its composition and prospects for each channel
 
 *Identify the growth prospects of key players in neighbourhood retailing
 
 *Analyse the key issues impacting the location and identify thestrategies for success

http://www.aarkstore.com/reports/UK-Neighbourhood-Retailing-2008-15800.html

Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second largest market

No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere. Big selling brands and now others in the same class are subject to special price cuts. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders. Whether the challenge is entering the Japanese market for the first time, moving up the all-important ranking there by market share, or negotiating with a local in-licensing partner, this report is designed to help. New drug pricing and price revision processes explained Written by an acknowledged expert on the Japanese market with 20 years’ experience Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008 Incorporates all pricing rule changes that came into effect from April 2008 Pro-generic measures critically appraised Key role of wholesalers and how they are paid clarified Prospects for future reform to the P&R processes discussed

http://www.aarkstore.com/reports/Pharmaceutical-Pricing-and-Distribution-in-Japan-The-keys-to-success-in-the-world’s-second-largest-market-1046.html

Access to Hospital Pharmaceutical Markets in the United Kingdom – Aarkstore Enterprise

Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe. They are the often the only market for the increasing numbers of speciality drugs emerging from R&D, with many primary care products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they have been poorly documented and often little understood. This justpharmareports’ publication aims to clarify the situation for the UK, a particularly challenging country with four different public healthcare systems, numerous stakeholders, regular reforms, and rigorous health technology assessment.

Medicines prescribed in English hospitals in 2006 were valued at £2.7 billion. This represented 24% of the English NHS drugs bill (hospital prescribing in London alone accounted for 40% of all prescribing costs in the capital). Even more significantly, the hospital drug bill has been rising at more than twice the rate of GP prescribing costs.

‘Access to Hospital Pharmaceutical Markets in the UK’ provides:

• Comprehensive and clear information on how medicines for hospital use get selected, purchased, distributed, prescribed, dispensed and paid for.
• Separate sections on England, Scotland, Wales and Northern Ireland.
• Full coverage of the NHS plus two of the largest private providers.
• Explanation of tendering, contracting, contract adjudication and other aspects of procurement for both brands and generics.
• Clarification of the complex English funding system, Payment by Results.
• Special focus on oncology.

• What discounts hospitals expect and why value-added tax is a concern.
• Features on risk-sharing schemes and on the boom in homecare services.
• NICE, SMC, AWMSG, the PPRS and much, much more

http://www.aarkstore.com/reports/Access-to-Hospital-Pharmaceutical-Markets-in-the-United-Kingdom-1052.html